Drug Design and Optimization

This group is located at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS)

 

In order to combat the increasing number of resistant pathogens, the development of new antibiotic drugs is an important goal for pharmaceutical research. Lacking in this field are efficient medications that fight infectious diseases. As a result, scientists are constructing and improving novel agents that target essential processes in bacteria. This is done with the aim of killing or attenuating these pathogens. Below, you may read more about the optimization of new drug candidates.

Research Projects

  • Development of potent inhibitors of the bacterial RNA polymerase for the treatment of infections with Mycobacterium tuberculosis: RNAP
  • Development of molecules that interfere with the PQS quorum sensing communication system in Pseudomonas aeruginosa: PQS QUORUM SENSING COMMUNICATION SYSTEM
  • Helmholtz Drug Research Initiative: DRUG RESEARCH

Leader

  • Prof Dr Rolf W. Hartmann

    Rolf Hartmann

    Head of the Department Drug Design and Optimization

    +49 681 98806-2000

    + 49 681 98806-2009

    Contact

    CV and Publications

News

Bachelor & Master
Are you interested in a bachelor or master thesis? We are looking forward to your request!

Audio Podcast

  • Kündigung für Biofilm-WGs – Pharmazeuten des HIPS stören Bakteriengemeinschaften
    Bakterien haben einen ausgeprägten Gemeinschaftssinn und verschanzen sich gerne in schleimigen Biofilmen. Etwa 60 Prozent aller bakteriellen Infektionen lösen inzwischen Biofilme aus. Ein besonders geselliger Keim ist Pseudomonas aeruginosa. Er ist besonders für Mukoviszidose-Patienten gefährlich. Wissenschaftler am Helmholtz-Institut für Pharmazeutische Forschung Saarland suchen nach Wegen, seine Biofilme aufzulösen – damit Medikamente wirken können. Begleiten Sie Anke Steinbach in Ihre Labore...